Exercise Intolerance in Heart Failure: the Role of Altered Cardiac and Skeletal Muscle Energetics
Overview
- Phase
- Not Applicable
- Intervention
- Hypertensive Subjects
- Conditions
- Heart Failure With Normal Ejection Fraction
- Sponsor
- Johns Hopkins University
- Enrollment
- 130
- Locations
- 1
- Primary Endpoint
- Skeletal muscle mitochondrial function
- Status
- Recruiting
- Last Updated
- last month
Overview
Brief Summary
The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.
Detailed Description
This research is being done to better understand why patients with heart failure have difficulty exercising and performing some activities of daily living. Heart muscle and skeletal muscle (in the legs and arms) depend on normal metabolism (the conversion of foods to chemical fuel) to function properly. Investigators will measure metabolites in the heart and leg muscles, including the levels of high energy phosphates and lipids (fats) using magnetic resonance (MR) techniques. High-energy phosphates serve as a source of energy, which is used by the heart and skeletal muscle for contraction. Magnetic resonance uses magnetic fields to measure the levels of these substances.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients of either gender who are greater than 21 years of age (no upper age limit),
- •Permission of patient's clinical attending physician,
- •Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class II-III symptoms for at least 1 month,
- •Left ventricular ejection fraction (EF) \>50% by echocardiography, MRI, CT or x-ray or nuclear ventriculography within prior 12 months,
- •Stable medical therapy for at least 30 days (no addition or removal or major (\>100%) dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers, or calcium channel blockers for hypertension).
Exclusion Criteria
- •Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent,
- •Contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,
- •Significant valvular abnormalities,
- •Pregnant women (women of childbearing potential will undergo blood or urine pregnancy testing),
- •History of clinical CAD or significant epicardial coronary disease (\>50% stenosis) in major coronary artery by x-ray or CT angiography unless (a) the patient underwent prior successful revascularization with percutaneous coronary angioplasty within the prior three years and (b) there are no residual lesions of \>50% on the most recent coronary angiographic study.
- •History of infiltrative cardiomyopathy or constrictive pericarditis,
- •Cor pulmonale,
- •Significant pulmonary disease,
- •Estimated glomerular filtration rate (eGFR) \<20ml/min,
- •Any condition other than HF which could limit the ability to perform a 6MW or cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease, significant orthopedic or neurological conditions),
Arms & Interventions
Hypertensive Subjects
Participants with Hypertension
HFpEF
Participants with Heart Failure with Preserved Ejection Fraction
HFrEF
Participants with Heart Failure with Reduced Ejection Fraction
Healthy Subjects
Participants without heart failure and without commodities
Outcomes
Primary Outcomes
Skeletal muscle mitochondrial function
Time Frame: Baseline
Maximal oxidative capacity of leg muscle measured by 31P Magnetic Resonance Spectroscopy (MRS)
Skeletal muscle energetic decline during exercise
Time Frame: Baseline
Creatine phosphate rate of decline (umol/g/min) during plantar flexion exercise measured by 31P MRS
Cardiac muscle energetics
Time Frame: Baseline
Cardiac muscle phosphocreatine (PCr)/ adenosine triphosphate (ATP) and creatine kinase(CK) flux (umol/g/s) measured by 31P MRS
Secondary Outcomes
- Cardiopulmonary exercise testing (CPET)(Six months)
- Six minute walk test(Six months)
- Clinical heart failure outcome as assessed by time to cardiovascular death(Two years)
- Clinical heart failure outcome as assessed by overall mortality(Two years)
- Clinical heart failure outcome as assessed by number of hospitalizations(Two years)